Sign In
Buy TGTX
$40.11
+3.47 (+9.47%)
At Close: Jun 03, 2026
TG Therapeutics (TGTX) Reports Q3 Loss, Misses Revenue Estimates
09:57am, Thursday, 04'th Nov 2021
TG Therapeutics (TGTX) delivered earnings and revenue surprises of -16.07% and -37.09%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
TG Therapeutics to Host Conference Call on Third Quarter 2021 Financial Results and Business Update
07:30am, Monday, 01'st Nov 2021
Conference call to be held Thursday, November 4, 2021 at 8:30 AM ET Conference call to be held Thursday, November 4, 2021 at 8:30 AM ET
New ULTIMATE I & II data presented at ECTRIMS shows ublituximab treatment is associated with significant improvement in the multiple sclerosis functional composite (MSFC) score
NEW YORK, Sept. 30, 2021 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (F
The ULTIMATE I & II Phase 3 trials both have met their primary endpoint with ublituximab treatment demonstrating a statistically significant reduction in annualized relapse rate (ARR) over a 96-week p
TG Therapeutics to Participate in the 2021 Cantor Virtual Global Healthcare Conference
07:30am, Thursday, 23'rd Sep 2021
Fireside chat scheduled for 10:40 AM ET on Monday, September 27, 2021 Fireside chat scheduled for 10:40 AM ET on Monday, September 27, 2021
Investor & Analyst Virtual Event to Discuss Phase 1 U2 + Venetoclax Data to be held today, September 20, 2021 at 8:30 AM ET Investor & Analyst Virtual Event to Discuss Phase 1 U2 + Venetoclax Data to
TG Therapeutics: Amid Market Overreaction Is An Opportunity
08:39pm, Wednesday, 15'th Sep 2021
TG recently posted its 2Q2021 earnings report which shows interesting fundamental developments. It seemed that the market overreacted by significantly discounting the stock by over 20%. Despite modest
Investor & Analyst Virtual Event to Discuss Phase 1 U2 + Venetoclax Data to be held Monday, September 20, 2021 at 8:30 AM ET Investor & Analyst Virtual Event to Discuss Phase 1 U2 + Venetoclax Data to
TG Therapeutics to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference
09:00am, Thursday, 09'th Sep 2021
Fireside chat available for on demand download at 7:00 AM ET on Monday, September 13, 2021 Fireside chat available for on demand download at 7:00 AM ET on Monday, September 13, 2021
TG Therapeutics Announces Data Presentations at the Upcoming XIX International Workshop on Chronic Lymphocytic Leukemia (iwCLL)
07:30am, Monday, 30'th Aug 2021
NEW YORK, Aug. 30, 2021 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of four data presentations at the upcoming XIX International Workshop on Chronic Lymphocy
Do Options Traders Know Something About TG Therapeutics (TGTX) Stock We Don't?
11:26am, Monday, 16'th Aug 2021
Investors need to pay close attention to for TG Therapeutics (TGTX) stock based on the movements in the options market lately.
Why TG Therapeutics Shares Are Trading Lower Today
03:54pm, Monday, 02'nd Aug 2021
TG Therapeutics Inc (NASDAQ: TGTX) is trading lower Monday after the company announced worse-than-expected second-quarter financial results and H.C. Wainwright lowered its price target.
TG Therapeutics, Inc. (TGTX) CEO Mike Weiss on Q2 2021 Results - Earnings Call Transcript
03:36pm, Monday, 02'nd Aug 2021
TG Therapeutics, Inc. (TGTX) CEO Mike Weiss on Q2 2021 Results - Earnings Call Transcript
TG Therapeutics Stock Plunged As H.C. Wainwright Cuts Target Price After Disappointing Q2
03:17pm, Monday, 02'nd Aug 2021
H.C. Wainwright has lowered TG Therapeutics Inc's (NASDAQ:TGTX) price target to $84 from $89 and keeps a Buy rating on the stock. Analyst Edward White mentioned that Ukoniq (umbralisib) reven
